# Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

> **NCT06462365** · PHASE1 · RECRUITING · sponsor: **Tr1X, Inc.** · enrollment: 36 (estimated)

## Conditions studied

- Hematologic Malignancy
- GvHD
- GVHD,Acute
- GVHD, Chronic
- Hematopoietic Stem Cell Transplant
- Acute Lymphoblastic Leukemia, Adult B-Cell
- Acute Lymphoblastic Leukemia, Adult T-Cell
- Acute Myeloid Leukemia in Remission
- Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia, in Remission
- Cancer Remission

## Interventions

- **BIOLOGICAL:** TRX103

## Key facts

- **NCT ID:** NCT06462365
- **Lead sponsor:** Tr1X, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-08
- **Primary completion:** 2026-04-15
- **Final completion:** 2027-04-15
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06462365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06462365, "Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06462365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*